Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Non-Current Deferred Tax Liability (2016 - 2018)

Historic Non-Current Deferred Tax Liability for Apyx Medical (APYX) over the last 7 years, with Q4 2018 value amounting to $150000.0.

  • Apyx Medical's Non-Current Deferred Tax Liability fell 5923.91% to $150000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $150000.0, marking a year-over-year decrease of 5923.91%. This contributed to the annual value of $150000.0 for FY2018, which is 5923.91% down from last year.
  • Apyx Medical's Non-Current Deferred Tax Liability amounted to $150000.0 in Q4 2018, which was down 5923.91% from $368000.0 recorded in Q2 2018.
  • Apyx Medical's 5-year Non-Current Deferred Tax Liability high stood at $864000.0 for Q4 2016, and its period low was $150000.0 during Q4 2018.
  • Moreover, its 4-year median value for Non-Current Deferred Tax Liability was $564000.0 (2017), whereas its average is $507777.8.
  • Per our database at Business Quant, Apyx Medical's Non-Current Deferred Tax Liability surged by 1368.42% in 2016 and then plummeted by 5923.91% in 2018.
  • Over the past 4 years, Apyx Medical's Non-Current Deferred Tax Liability (Quarter) stood at $760000.0 in 2015, then rose by 13.68% to $864000.0 in 2016, then plummeted by 57.41% to $368000.0 in 2017, then tumbled by 59.24% to $150000.0 in 2018.
  • Its Non-Current Deferred Tax Liability was $150000.0 in Q4 2018, compared to $368000.0 in Q2 2018 and $368000.0 in Q1 2018.